Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9–59 years: A randomized, double-blind, controlled, phase IV clinical trial

• Published in: Vaccine 2024-08, Vol.42 (21), p.126182, Article 126182
• Main Authors: Gao, Yuanxue, Yang, Xinyi, Li, Xiaoyu, Chen, Hu, Li, Yuwei, Tan, Xue, Yu, Dan, Feng, Tian, Zhou, Siliang, Lei, Shiguang, Zhao, Chenyan, Wang, Jieru, Guan, Qinghu
• Format: Article
• Language: English
• Subjects: Adolescents; Analysis of covariance; Antibodies; Clinical trials; Deactivation; Demographics; Ethnicity; Guardians; Hemagglutination inhibition; Immune response; Immune system; Immunogenicity; Influenza; Lot-to-lot consistency; Manufacturing; Quadrivalent inactivated influenza vaccine; Ratios; Safety; Seroconversion; Vaccines; Virions
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2024.126182

This study was to assess the lot-to-lot consistency, immunogenicity and safety of three manufacturing lots of a quadrivalent inactivated influenza vaccine (IIV4). A randomized, double-blind, phase IV clinical trial was conducted in healthy children, adolescents and adults aged 9–59 years in Guizhou Province, China. Eligible participants were enrolled and randomized into three groups in a ratio of 1:1:1 to receive a single dose of one of three manufacturing lots of IIV4. Serum samples were collected before and 28 days after vaccination for hemagglutination inhibition (HI) antibody testing. Safety data were collected for up to 28 days after vaccination. The primary objective was to evaluate the lot-to-lot consistency of immune response as assessed by the geometric mean titer (GMT) of HI antibody at 28 days after vaccination. Between November 27, 2022 and December 18, 2022, 1260 eligible participants were enrolled, with similar participant demographics among groups. Immune responses after vaccination were comparable across groups, with the 95% confidence intervals (CIs) of GMT ratios for all 4 strains falling into the equivalence criterion of (0.67, 1.5). The seroconversion rates (SCRs) and seroprotection rates (SPRs) met the US Center or Biologics Evaluation and Research (CBER) criteria for all strains for each lot (lower limit of 95% CI of SCR ≥ 40% and SPR ≥ 70%). The incidences of solicited and unsolicited adverse reactions were similar among three groups, most of which (91.9%) were mild or moderate in severity. A total of 11 serious adverse events were reported during the study, and all were considered unrelated to vaccination. The three manufacturing lots of IIV4 demonstrated consistent immunogenicity. IIV4 can elicit satisfactory immune responses for all four strains and no safety concerns were identified. Clinical trial registration: Identifier No. NCT05512494. •The first lot-to-lot consistency study to demonstrate the stability of manufacturing process.•The first study to prove that IIV4 has good immunogenicity and safety in multi-ethnic population, such as Dong and Miao, other than Han in China.•IIV4 could induce good immune response in both adolescents and adults.•Vaccination with IIV4 did not increase additional safety risk.